Bayer, Evotec enter endometriosis drug deal potentially worth up to 592 million euros

Bayer announced Monday a deal with Evotec potentially worth up to 592 million euros ($763 million) to develop three drug candidates for the treatment of endometriosis. Head of global drug discovery at Bayer Andreas Bush noted that endometriosis "is one of Bayer's strategic research indications and our new collaboration with Evotec will perfectly complement our activities in this field of high unmet medical need."

Under the five-year collaboration, the companies will contribute drug targets and will share responsibility for early research and preclinical characterisation, with Bayer responsible for any subsequent clinical development and marketing. Bayer will pay Evotec 12 million euros ($15 million) upfront, as well as make milestone payments of up to approximately 580 million euros ($748 million). Evotec is also eligible to receive potential royalties of up to low double digit percent of net sales, depending on which party brought the compound to the collaboration and the successful development and approval of any drug candidates.

To read more Top Story articles, click here.